Global Reach Health – Page 85 – Global Reach Health

January 16, 2020

Ozempic Receives New Indication

January 16, 2020 – The U.S. FDA has approved a new indication for Ozempic® (semaglutide) injection 0.5mg or 1mg, manufactured by Novo Nordisk. Ozempic is now indicated to reduce the risk of major adverse cardiovascular events (MACE) such as heart

January 14, 2020

Eli Lilly to Offer Lower Price Alternatives for Two Additional Insulin Products

January 14, 2020 – Drug manufacturer Eli Lilly has announced that it will offer lower price versions of its brand name insulin products Humalog® Mix75/25TM KwikPen® (insulin lispro protamine/insulin

January 14, 2020

New Safety Warning Regarding Belviq and Belviq XR

January 14, 2020 – The U.S. FDA has issued a safety communication regarding Arena Pharmaceuticals’ Belviq® (lorcaserin) and Belviq® XR (lorcaserin extended release). According to the agency, these drugs may increase patients’ risk of cancer.

January 13, 2020

Numbrino Approved as a Local Anesthetic

January 13, 2020 – The U.S. FDA has approved Numbrino® (cocaine hydrochloride nasal solution 4%), a nasal spray manufactured by Lanett Company and indicated to provide local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.

January 13, 2020

Valtoco Approved to Treat Epilepsy

January 13, 2020 – The U.S. FDA has approved Valtoco® (diazepam nasal spray), manufactured by Neurelis Pharmaceuticals, to provide acute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters, acute repetitive seizures) that are distinct from a patient's usual

January 10, 2020

Taro Pharmaceuticals Recalls One Lot of Lamotrigine Tablets

January 10, 2020 – Taro Pharmaceuticals has announced the voluntary recall of one lot of Lamotrigine 100mg Tablets. Tablets in lot number 331771 (expiration date June 2021) have been found to be cross contaminated with another drug

January 9, 2020

Ayvakit Approved as First Targeted Therapy for Gastrointestinal Tumors with Rare Gene Mutation

January 9, 2020 – The U.S. FDA has approved AyvakitTM (avapritinib), manufactured by Blueprint Medicines Corporation, to treat adult patients who have unresectable or metastatic gastrointestinal

January 8, 2020

Keytruda Receives New Bladder Cancer Indication

January 8, 2020 – The U.S. FDA has approved a new indication for Keytruda® (pembrolizumab), manufactured by Merck, to treat patients who are ineligible for or have elected not to undergo cystectomy and have been diagnosed with high-risk, non-muscle invasive bladder cancer (NMIBC)